Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been shown to improve survival, whereas β-blockers have not been shown to benefit recovery despite frequent use [1]. Anticoagulation can be prescribed for patients at high risk for thromboembolism, and antiplatelet agents such as aspirin can be used, though there is no evidence to suggest cardiovascular benefit [1]. The gene discussed is ACE; the disease is Thromboembolism.